PeptiDream Inc. (PPTDF) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

PeptiDream Inc. (PPTDF) Healthcare & Pipeline Overview

PeptiDream Inc. is a Japanese biopharmaceutical company focused on discovering and developing novel therapeutics using its proprietary Peptide Discovery Platform System. With a focus on constrained peptides, small molecules, and peptide-drug conjugates, PeptiDream collaborates with major pharmaceutical companies like Takeda to advance drug candidates, primarily targeting neuromuscular diseases.

What Is the Investment Thesis for PPTDF?

PeptiDream Inc. presents a compelling investment thesis centered on its innovative Peptide Discovery Platform System and strategic collaborations with major pharmaceutical companies. The company's ability to generate novel peptide-based therapeutics offers significant potential for long-term growth. Key value drivers include the expansion of its partnered programs, advancement of internal pipeline candidates, and continued innovation in its platform technology. The collaboration with Takeda Pharmaceutical Company Limited, focused on peptide-drug conjugates for neuromuscular diseases, highlights the potential of PeptiDream's technology. However, the company's negative profit margin of -20.2% and high P/E ratio of -46.57 indicate current challenges in achieving profitability. Investors should closely monitor the progress of clinical trials, partnership expansions, and the company's ability to translate its platform technology into commercially successful products. The company's low beta of 0.04 suggests low volatility relative to the market.

Based on FMP financials and quantitative analysis

PPTDF Key Highlights

PeptiDream Inc. operates with 621 employees, indicating a substantial operational capacity for research and development.

• The company's market capitalization stands at $1.13 billion, reflecting investor valuation of its technology and pipeline.
• A gross margin of 40.6% demonstrates the potential profitability of PeptiDream's partnered programs, despite the current negative profit margin.
• The company's P/E ratio is -46.57, reflecting the company's current lack of profitability.
• PeptiDream has a collaborative research and exclusive license agreement with Takeda Pharmaceutical Company Limited, highlighting its ability to attract major pharmaceutical partners.

Who Are PPTDF's Competitors?

PPTDF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are PPTDF's Key Strengths?

Proprietary Peptide Discovery Platform System (PDPS).

• Strong collaborative partnerships with major pharmaceutical companies.
• Expertise in peptide engineering and drug development.
• Focus on constrained peptides, offering enhanced stability and target specificity.

What Are PPTDF's Weaknesses?

Negative profit margin (-20.2%).

• High P/E ratio (-46.57), indicating a lack of current profitability.
• Reliance on collaborative partnerships for funding and development.
• Limited number of approved products on the market.

What Could Drive PPTDF Stock Higher?

Clinical trial results for key pipeline candidates could drive significant stock movement.

• Expansion of collaborative partnerships with pharmaceutical companies could provide additional funding and validation of PeptiDream's technology.
• Advancements in the Peptide Discovery Platform System (PDPS) could lead to the discovery of new drug candidates.
• Regulatory approvals for any of PeptiDream's drug candidates would be a major catalyst.
• Increased investor awareness of PeptiDream's technology and potential could drive increased stock valuation.

What Are the Key Risks for PPTDF?

Negative return on equity (-6.9%) — the business is not currently generating profit on shareholder capital.

• Inconsistent delivery — missed Wall Street EPS estimates in 6 of the last 8 reported quarters.
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Failure of clinical trials for key pipeline candidates could negatively impact the company's value.
• Competition from other biotechnology companies with similar technologies could limit PeptiDream's market share.
• Regulatory hurdles and lengthy drug approval processes could delay the commercialization of PeptiDream's products.
• Reliance on collaborative partnerships for funding and development creates dependence on external factors.
• The company's negative profit margin and high P/E ratio indicate current challenges in achieving profitability.

What Are the Growth Opportunities for PPTDF?

• Expansion of Collaborative Partnerships: PeptiDream has the opportunity to expand its network of collaborative partnerships with pharmaceutical companies. By leveraging its Peptide Discovery Platform System, PeptiDream can generate novel peptide-based therapeutics for a wide range of disease targets. Securing new partnerships would provide additional funding for research and development, accelerate the advancement of its pipeline, and increase its market reach. The global market for pharmaceutical collaborations is projected to reach $70 billion by 2028, offering significant potential for PeptiDream.
• Advancement of Internal Pipeline Candidates: PeptiDream can focus on advancing its own internal pipeline of drug candidates. By selecting promising leads from its platform and investing in preclinical and clinical development, PeptiDream can create proprietary assets with the potential for high returns. The company's expertise in peptide engineering and drug development provides a competitive advantage in this area. The global market for peptide therapeutics is expected to reach $45 billion by 2030, creating a substantial opportunity for PeptiDream's internal pipeline.
• Development of Peptide-Drug Conjugates (PDCs): PeptiDream's expertise in peptide engineering makes it well-positioned to develop novel peptide-drug conjugates (PDCs). PDCs combine the targeting specificity of peptides with the cytotoxic activity of small molecule drugs, offering a powerful approach for cancer therapy and other diseases. The company's collaboration with Takeda Pharmaceutical Company Limited in this area demonstrates the potential of its PDC platform. The global market for antibody-drug conjugates (ADCs), a related class of therapeutics, is projected to reach $20 billion by 2028, indicating the significant potential of the PDC market.
• Application of Platform to New Therapeutic Areas: PeptiDream can expand the application of its Peptide Discovery Platform System to new therapeutic areas beyond its current focus. By adapting its platform to address unmet medical needs in areas such as autoimmune diseases, infectious diseases, and neurological disorders, PeptiDream can broaden its market reach and create new revenue streams. The global market for therapeutics in these areas is substantial, offering significant growth opportunities for PeptiDream.
• Licensing of Platform Technology: PeptiDream can explore opportunities to license its Peptide Discovery Platform System to other companies. By providing access to its platform technology, PeptiDream can generate revenue from licensing fees and royalties. This would allow other companies to leverage PeptiDream's expertise in peptide engineering and drug discovery, while also providing PeptiDream with a recurring revenue stream. The market for drug discovery technologies is growing, driven by the increasing demand for innovative approaches to drug development.

What Are PPTDF's Competitive Advantages?

• Proprietary Peptide Discovery Platform System (PDPS): This platform provides a unique and efficient method for discovering and developing constrained peptides.
• Strong collaborative partnerships: Collaborations with major pharmaceutical companies like Takeda validate the value of PeptiDream's technology and provide access to funding and expertise.
• Expertise in peptide engineering: PeptiDream's team has deep expertise in peptide engineering, enabling the creation of novel and effective peptide-based therapeutics.
• Intellectual property portfolio: PeptiDream has a strong intellectual property portfolio protecting its platform technology and drug candidates.

What Does PPTDF Do?

PeptiDream Inc., established in 2006 and headquartered in Kawasaki, Japan, is a biopharmaceutical company dedicated to the discovery and development of innovative therapeutics. The company's core technology is its proprietary Peptide Discovery Platform System (PDPS), a versatile drug discovery platform enabling the rapid identification and optimization of constrained peptides. These peptides serve as the foundation for developing various therapeutic modalities, including small molecules and peptide-drug conjugates (PDCs). PeptiDream's business model centers around forming collaborative research and licensing agreements with leading pharmaceutical companies. A notable example is their partnership with Takeda Pharmaceutical Company Limited, focused on developing PDCs for neuromuscular diseases. This collaboration exemplifies PeptiDream's strategy of leveraging its PDPS to generate novel drug candidates and partnering with established players to advance these candidates through clinical development and commercialization. PeptiDream's focus on constrained peptides allows for the creation of molecules with enhanced stability, target specificity, and therapeutic potential. The company continues to expand its platform capabilities and broaden its network of partnerships to address unmet medical needs across a range of therapeutic areas.

What Products and Services Does PPTDF Offer?

• Discovers and develops constrained peptides for therapeutic applications.
• Develops small molecule therapeutics based on its proprietary platform.
• Creates peptide-drug conjugates (PDCs) for targeted drug delivery.
• Utilizes its Peptide Discovery Platform System (PDPS) for drug discovery.
• Forms collaborative research agreements with pharmaceutical companies.
• Licenses its technology to other companies for drug development.
• Focuses on developing therapeutics for neuromuscular diseases through its collaboration with Takeda.

How Does PPTDF Make Money?

• Generates revenue through collaborative research and licensing agreements with pharmaceutical companies.
• Receives upfront payments, milestone payments, and royalties from its partnered programs.
• Develops and out-licenses its proprietary drug candidates.
• Potentially generates revenue from direct sales of its own approved therapeutics in the future.

What Industry Does PPTDF Operate In?

PeptiDream Inc. operates within the biotechnology industry, a sector characterized by intense research and development, high regulatory hurdles, and significant growth potential. The market for peptide therapeutics is expanding, driven by the increasing demand for targeted therapies and advancements in peptide engineering. PeptiDream's Peptide Discovery Platform System positions it to capitalize on this trend. Competitors include companies like CSBTF (Creative Biolabs), CSPHF (Capricor Therapeutics), GENSF (Genscript Biotech Corp), MEOBF (MeoVac), and NURPF (Neuropore Therapies), each with their own unique technology platforms and therapeutic focuses. The industry is also influenced by factors such as regulatory changes, technological advancements, and the increasing prevalence of chronic diseases.

Who Are PPTDF's Key Customers?

• Takeda Pharmaceutical Company Limited (collaborative partner).
• Other pharmaceutical companies seeking novel peptide-based therapeutics.
• Potential future customers include patients who would benefit from PeptiDream's therapies.
• Licensing partners who utilize PeptiDream's platform for their own drug discovery efforts.

Wall Street analysts project PeptiDream Inc. revenue of about $41.63B for fiscal 2026, with EPS near $79.87. The estimate reflects 7 contributing analysts.

PeptiDream Inc. has missed Wall Street's EPS estimate in 6 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 88.1% below estimates on average.

PeptiDream Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 4.44 places it in the safe zone, indicating low near-term bankruptcy risk.

Return on equity for PeptiDream Inc. stands at -6.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -4.8%, showing how much profit it generates from its asset base. Its free cash flow yield is -4.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.06 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -2.8%, the inverse of the P/E and a quick read on earnings relative to price.

PeptiDream Inc. (PPTDF) Valuation Context

Valued at $861M, PPTDF is classified as a small-cap stock. Relative to its peer group, PPTDF's quantitative score of 51/100 is roughly in line with the peer average of 55/100.

PPTDF Revenue & Earnings Trend

In Q2 2026, PPTDF generated $4.43B in top-line revenue, marking a sequential decrease of 7.6%. The company recorded a net loss of $1.14B, with diluted EPS of $-8.83. Revenue has contracted over three consecutive quarters, which investors in this small-cap Healthcare stock should monitor closely. Across the four most recent quarters, PPTDF averaged $-7.05 in diluted EPS.

Company Profile

PeptiDream Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Kawasaki, JP. The company is led by CEO Patrick Crawford Reid. PPTDF has traded publicly since 2014.

PPTDF Financials

PPTDF Latest News

No recent news available for PPTDF.

PPTDF Analyst Consensus

PPTDF MoonshotScore

PPTDF Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources